DK0900088T3 - Inklusionskomplekser af arylheterocykliske salte - Google Patents

Inklusionskomplekser af arylheterocykliske salte

Info

Publication number
DK0900088T3
DK0900088T3 DK97907246T DK97907246T DK0900088T3 DK 0900088 T3 DK0900088 T3 DK 0900088T3 DK 97907246 T DK97907246 T DK 97907246T DK 97907246 T DK97907246 T DK 97907246T DK 0900088 T3 DK0900088 T3 DK 0900088T3
Authority
DK
Denmark
Prior art keywords
arylheterocyclic
salts
inclusion complexes
complexes
inclusion
Prior art date
Application number
DK97907246T
Other languages
Danish (da)
English (en)
Inventor
Kevin Charles Johnson
Yesook Kim
Ravi Mysore Shanker
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0900088T3 publication Critical patent/DK0900088T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Machine Translation (AREA)
  • Seasonings (AREA)
  • Soil Conditioners And Soil-Stabilizing Materials (AREA)
DK97907246T 1996-05-07 1997-04-01 Inklusionskomplekser af arylheterocykliske salte DK0900088T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1920496P 1996-05-07 1996-05-07
PCT/IB1997/000321 WO1997041896A2 (en) 1996-05-07 1997-04-01 Inclusion complexes of aryl-heterocyclic salts

Publications (1)

Publication Number Publication Date
DK0900088T3 true DK0900088T3 (da) 2004-04-19

Family

ID=21791976

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97907246T DK0900088T3 (da) 1996-05-07 1997-04-01 Inklusionskomplekser af arylheterocykliske salte

Country Status (47)

Country Link
US (2) US6232304B1 (cs)
EP (1) EP0900088B1 (cs)
JP (1) JP3579060B2 (cs)
KR (1) KR20000010823A (cs)
CN (1) CN1216923A (cs)
AP (1) AP796A (cs)
AR (2) AR007002A1 (cs)
AT (1) ATE257714T1 (cs)
AU (1) AU713711B2 (cs)
BG (3) BG64475B2 (cs)
BR (1) BR9709213A (cs)
CA (1) CA2251912C (cs)
CO (1) CO4600677A1 (cs)
CZ (1) CZ297847B6 (cs)
DE (1) DE69727218T2 (cs)
DK (1) DK0900088T3 (cs)
DZ (1) DZ2220A1 (cs)
EA (1) EA001731B1 (cs)
EG (1) EG24135A (cs)
ES (1) ES2212809T3 (cs)
GE (1) GEP20074185B (cs)
GT (1) GT199700044A (cs)
HN (1) HN1997000039A (cs)
HR (1) HRP970237B1 (cs)
HU (1) HU222451B1 (cs)
ID (1) ID16866A (cs)
IL (1) IL126546A (cs)
IS (1) IS2524B (cs)
MA (1) MA24172A1 (cs)
ME (1) ME00880B (cs)
MY (1) MY121999A (cs)
NO (1) NO324373B1 (cs)
NZ (1) NZ332220A (cs)
OA (1) OA10907A (cs)
PL (1) PL189324B1 (cs)
PT (1) PT900088E (cs)
RS (1) RS49532B (cs)
SA (1) SA97180024B1 (cs)
SI (1) SI0900088T1 (cs)
SK (1) SK282032B6 (cs)
TN (1) TNSN97075A1 (cs)
TR (1) TR199802231T2 (cs)
TW (1) TW514529B (cs)
UA (1) UA57734C2 (cs)
UY (1) UY24544A1 (cs)
WO (1) WO1997041896A2 (cs)
ZA (1) ZA973874B (cs)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
DK0811386T3 (da) * 1996-05-07 2005-01-03 Pfizer Fremgangsmåde til udvælgelse af et salt til fremstilling af et inklusionskompleks
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
JP4503724B2 (ja) * 1999-05-10 2010-07-14 栄研化学株式会社 ホタルルシフェリンの安定化方法
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
US6884885B2 (en) 2000-12-21 2005-04-26 Cerestar Holding B.V. Production of cyclodextrin complexes
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
SI1542668T1 (sl) * 2002-08-20 2009-08-31 Bristol Myers Squibb Co Aripiprazol sestavljena formulacija in postopek
PL375981A1 (en) * 2002-09-17 2005-12-12 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
BR0315568A (pt) * 2002-10-25 2005-08-23 Pfizer Prod Inc Formulações de depósito injetáveis
WO2004037224A1 (en) * 2002-10-25 2004-05-06 Pfizer Products Inc. Depot formulations of arylheterocyclic active agents in the form of a suspension
US20040142039A1 (en) * 2002-10-31 2004-07-22 Pfizer Inc Solid and semi-solid polymeric ionic conjugates
JP2006506396A (ja) * 2002-10-31 2006-02-23 ファイザー・プロダクツ・インク 固体医薬の液体複合体
MXPA03009945A (es) 2002-11-05 2007-04-16 Lg Electronics Inc Montaje para montar una pantalla de toque para un monitor con pantalla de cristal liquido.
CN1255105C (zh) * 2002-12-17 2006-05-10 上海医药工业研究院 齐拉西酮及其盐的水溶性包合物及其制备方法
CA2528100A1 (en) * 2003-06-03 2005-04-21 Teva Pharmaceutical Industries Ltd Polymorphic forms of ziprasidone hcl and processes for their preparation
EP1663166A2 (en) * 2003-09-02 2006-06-07 Imran Ahmed Sustained release dosage forms of ziprasidone
JP2007513202A (ja) * 2003-12-08 2007-05-24 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アリゾナ 相乗的な抗癌組成物
US20050163858A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Ziprasidone formulations
SI21703A (en) * 2004-01-14 2005-08-31 Lek Farmacevtska Druzba Dd Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia
EP1744750A2 (en) 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
WO2006032957A1 (en) * 2004-05-26 2006-03-30 Pfizer Products Inc. In vitro predictive method
EP1753400A4 (en) * 2004-06-11 2012-11-28 Reddys Lab Ltd Dr PHARMACEUTICAL FOR ZIPRASIDONE
KR20130030305A (ko) * 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
EP1863806A1 (en) * 2005-02-11 2007-12-12 Teva Pharmaceutical Industries Ltd Amorphous ziprasidone mesylate
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICULAR COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES
EP1858892A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Anhydrous ziprasidone mesylate and a process for its preparation
US20060270684A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Crystalline forms of ziprasidone mesylate
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
KR20170091770A (ko) 2006-07-10 2017-08-09 파이온 유케이 리미티드 속효형 벤조디아제핀 염 및 이의 중합체 형태
MX2009011681A (es) * 2007-05-18 2009-11-10 Scidose Llc Formulaciones de ziprasidona.
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
CN101314045B (zh) * 2008-05-09 2013-01-23 沈阳药科大学 桂利嗪的磺丁基醚-β-环糊精包合物及其制剂和制备方法
US20130108701A1 (en) 2010-05-25 2013-05-02 Krishna Murthy Bhavanasi Solid Dosage Forms of Antipsychotics
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
CN102793701B (zh) * 2011-05-25 2014-12-17 上海医药工业研究院 卢拉西酮组合物
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
WO2023108156A1 (en) * 2021-12-11 2023-06-15 Beloteca, Inc. Ziprasidone formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
IT1196033B (it) 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1255462B (it) 1992-07-28 1995-11-02 Grazia Maffione Metodo di preparazione di composti di inclusione di nimesulide con ciclodestrine
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
HU210922B (en) 1993-05-24 1995-09-28 Europharmaceuticals Sa Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them
IT1269578B (it) 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
BE1008307A3 (fr) 1994-06-16 1996-04-02 Europharmaceuticals Sa Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
DK0811386T3 (da) 1996-05-07 2005-01-03 Pfizer Fremgangsmåde til udvælgelse af et salt til fremstilling af et inklusionskompleks
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL126590A (en) 1996-05-07 2001-11-25 Pfizer Trihydrate salt of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, 3-dihydro-2 (1H) - indole - 2On (= Ziprasidone) and pharmaceutical preparations containing it
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物

Also Published As

Publication number Publication date
BG102894A (en) 1999-09-30
HU222451B1 (hu) 2003-07-28
AP9700977A0 (en) 1997-07-31
MY121999A (en) 2006-03-31
BG64475B1 (bg) 2005-04-30
HRP970237B1 (en) 2002-04-30
SA97180024B1 (ar) 2005-12-24
UA57734C2 (uk) 2003-07-15
AU1937297A (en) 1997-11-26
NO324373B1 (no) 2007-10-01
ME00880B (me) 2006-12-15
US20010031756A1 (en) 2001-10-18
WO1997041896A2 (en) 1997-11-13
JPH11509866A (ja) 1999-08-31
SK282032B6 (sk) 2001-10-08
TW514529B (en) 2002-12-21
CZ346198A3 (cs) 1999-09-15
HUP9902799A3 (en) 2000-12-28
DE69727218T2 (de) 2004-11-18
CA2251912C (en) 2003-06-03
IS4880A (is) 1998-10-27
TNSN97075A1 (fr) 2005-03-15
CN1216923A (zh) 1999-05-19
EG24135A (en) 2008-08-06
IS2524B (is) 2009-07-15
CO4600677A1 (es) 1998-05-08
ID16866A (id) 1997-11-20
WO1997041896A3 (en) 1998-01-08
AR045528A2 (es) 2005-11-02
SK150498A3 (en) 2000-01-18
TR199802231T2 (xx) 1999-02-22
PL329928A1 (en) 1999-04-26
CA2251912A1 (en) 1997-11-13
BG64474B1 (bg) 2005-04-30
EP0900088A2 (en) 1999-03-10
JP3579060B2 (ja) 2004-10-20
US6232304B1 (en) 2001-05-15
EA199800910A1 (ru) 1999-04-29
NO985192D0 (no) 1998-11-06
DE69727218D1 (de) 2004-02-19
HRP970237A2 (en) 1998-12-31
YU17297A (sh) 1999-12-27
ZA973874B (en) 1998-11-06
ES2212809T3 (es) 2004-08-01
KR20000010823A (ko) 2000-02-25
US6399777B2 (en) 2002-06-04
PT900088E (pt) 2004-04-30
NO985192L (no) 1998-11-06
OA10907A (en) 2001-10-26
NZ332220A (en) 2000-03-27
CZ297847B6 (cs) 2007-04-11
IL126546A0 (en) 1999-08-17
MA24172A1 (fr) 1997-12-31
AU713711B2 (en) 1999-12-09
ATE257714T1 (de) 2004-01-15
GT199700044A (es) 1998-10-02
HN1997000039A (es) 1997-06-26
HUP9902799A2 (hu) 1999-12-28
AP796A (en) 1999-12-24
PL189324B1 (pl) 2005-07-29
UY24544A1 (es) 2000-09-29
BR9709213A (pt) 1999-08-10
AR007002A1 (es) 1999-10-13
GEP20074185B (en) 2007-08-10
SI0900088T1 (en) 2004-04-30
EA001731B1 (ru) 2001-08-27
EP0900088B1 (en) 2004-01-14
IL126546A (en) 2001-01-28
BG64475B2 (bg) 2005-04-30
RS49532B (sr) 2006-12-15
DZ2220A1 (fr) 2002-12-03

Similar Documents

Publication Publication Date Title
DK0900088T3 (da) Inklusionskomplekser af arylheterocykliske salte
DK0876622T3 (da) Sporing af grupper
DE69725631D1 (de) Laser-Nivelliervorrichtung
ID19609A (id) Senyawa-senyawa heterosiklik
ID19403A (id) Senyawa-senyawa heterosiklik
ID16152A (id) Senyawa-senyawa triaril
EE200000031A (et) Uued spiroasabitsüklilised heterotsüklilised ühendid
DK0882071T3 (da) Syntese af forgrenede polymerer
ID15904A (id) Senyawa-senyawa tiofenopirimidina
BR9710352A (pt) Compostos piridilpirrole
DE69716924D1 (de) Phosphonat-nukleotid-verbindungen
ID18685A (id) Senyawa trisiklik tersubstitusi
DE69724164D1 (de) Servoschaltung
PT906288E (pt) Novos compostos
DE69726225D1 (de) Leseschaltung
BR9705635A (pt) Compostos
DK0923594T3 (da) Bromotiacumicinforbindelser
DE69724293D1 (de) Metallo-porphyrinen
DE69709659D1 (de) Halopropargyl-einschlussverbindungen
DE59706129D1 (de) Tensidhaltige formulierungen
EE9900012A (et) Uudsed ühendid
DE69515735D1 (de) Phasenkomparator
DK0927163T3 (da) Fremstilling af 1-butyl-4-piperidinylmethylamin
DK0913063T3 (da) Validering af procedurer
FR2752100B1 (fr) Laser